Pancreatic adenocarcinoma, Version 2.2021

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. KunstmanNoelle LoConte, Andrew M. Lowy1, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer, Robert A. Wolff, Brian M. Wolpin, Beth Lynn, Giby V. George

Research output: Contribution to journalReview articlepeer-review

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.

Original languageEnglish (US)
Pages (from-to)439-457
Number of pages19
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number4
DOIs
StatePublished - Apr 2021
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Pancreatic adenocarcinoma, Version 2.2021'. Together they form a unique fingerprint.

Cite this